BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 31138506)

  • 1. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
    Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
    Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two different patterns of lung adenocarcinoma with concomitant
    Zhao D; Fan J; Peng L; Huang B; Zhu Y; Shi H; Dai X; Nie X
    Tumori; 2022 Feb; 108(1):12-18. PubMed ID: 33818198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.
    Fan J; Wu J; Huang B; Zhu Y; Shi H; Dai X; Nie X
    Diagn Pathol; 2020 May; 15(1):42. PubMed ID: 32375829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
    Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
    Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in non-small cell lung cancer patients from eastern India.
    Mohapatra PR; Sahoo S; Bhuniya S; Panigrahi MK; Majumdar SKD; Mishra P; Patra S
    J Cancer Res Ther; 2020; 16(4):850-854. PubMed ID: 32930129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
    Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
    J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
    Xu L; Lei J; Wang QZ; Li J; Wu L
    Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer.
    Wang Z; Zhang X; Bai H; Zhao J; Zhuo M; An T; Duan J; Yang L; Wu M; Wang S; Wang Y; Wu Y; Wang J
    Oncology; 2012; 83(5):248-56. PubMed ID: 22964709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.
    Mitiushkina NV; Iyevleva AG; Poltoratskiy AN; Ivantsov AO; Togo AV; Polyakov IS; Orlov SV; Matsko DE; Novik VI; Imyanitov EN
    Cancer Cytopathol; 2013 Jul; 121(7):370-6. PubMed ID: 23408463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?
    Halpenny DF; Riely GJ; Hayes S; Yu H; Zheng J; Moskowitz CS; Ginsberg MS
    Lung Cancer; 2014 Nov; 86(2):190-4. PubMed ID: 25312988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.
    Fan J; Dai X; Nie X
    J Thorac Oncol; 2018 Mar; 13(3):e45-e48. PubMed ID: 29472061
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
    Wang WT; Li Y; Ma J; Chen XB; Qin JJ
    Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
    Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
    Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
    Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
    Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing.
    Kheng YC; Walsh K; Williams L; Wallace WA; Harrison DJ; Oniscu A
    J R Coll Physicians Edinb; 2018 Mar; 48(1):20-24. PubMed ID: 29741520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.